Belpointe Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Belpointe Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$556K	Buy	+13,216	New	+$421K	0.02%	690
2025 Q1	–	Sell	-12,869	Closed	-$340K	–	922
2024 Q4	$340K	Sell	12,869 -8	-0.1%	-$197	0.02%	615
2024 Q3	$330K	Buy	12,877 +3,409	+36%	+$86.8K	0.02%	637
2024 Q2	$222K	Buy	9,468 +1,826	+24%	+$46.1K	0.02%	688
2024 Q1	$220K	Buy	+7,642	New	+$230K	0.02%	709
2023 Q2	–	Sell	-21,610	Closed	-$650K	–	749
2023 Q1	$650K	Sell	21,610 -33,623	-61%	-$1.04M	0.04%	454
2022 Q4	$1.56M	Buy	55,233 +25,235	+84%	+$801K	0.09%	221
2022 Q3	$986K	Buy	+29,998	New	+$1.1M	0.07%	297
2022 Q2	–	Sell	-4,462	Closed	-$206K	–	1137
2022 Q1	$206K	Sell	4,462 -464	-9%	-$22.1K	0.01%	894
2021 Q4	$302K	Sell	4,926 -234	-5%	-$16.2K	0.02%	707
2021 Q3	$385K	Sell	5,160 -3,339	-39%	-$280K	0.03%	594
2021 Q2	$787K	Buy	8,499 +3,722	+78%	+$316K	0.06%	353
2021 Q1	$424K	Sell	4,777 -4,009	-46%	-$398K	0.04%	483
2020 Q4	$819K	Buy	+8,786	New	+$700K	0.07%	290

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Belpointe Asset Management's ARKG Position: Q2 2026 in Review

Belpointe Asset Management opened a new position in ARK Genomic Revolution ETF (ARKG) in Q2 2026: 13,216 shares worth $556K. The stake represents 0.02% of the portfolio and ranks #690 among its holdings. This is a return to the name: Belpointe Asset Management previously reported a position in ARKG as recently as Q4 2024.

Belpointe Asset Management first reported a position in ARKG in Q4 2020 and has held it in 14 quarters since. The position peaked at $1.56M in Q4 2022. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Belpointe Asset Management held 13,216 shares of ARK Genomic Revolution ETF worth $556K as of Q2 2026.
ARK Genomic Revolution ETF was a new Belpointe Asset Management position in Q2 2026.
ARK Genomic Revolution ETF made up 0.02% of Belpointe Asset Management's portfolio in Q2 2026, its #690 holding.
Belpointe Asset Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and has held it in 14 quarters since.
Belpointe Asset Management's ARK Genomic Revolution ETF position peaked at $1.56M in Q4 2022.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.